<DOC>
	<DOC>NCT01435382</DOC>
	<brief_summary>This Phase 1 study has been designed to evaluate the absolute bioavailability of PF-04950615 in subjects with hypercholesterolemia who are not currently on lipid-lowering therapy.</brief_summary>
	<brief_title>A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 in Subjects With Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Lipid Metabolism Disorders</mesh_term>
	<criteria>Fasting LDLC greater than or equal to 130 mg/dL at two qualifying screening visits. Total body weight greater than or equal to 50 kg (110 lbs) and less than or equal to 150 kg (330 lbs) Lipidlowering prescription medications, homeopaths, herbal medicines, or nutritional supplements. Poorly controlled type 1 or type 2 diabetes. History of a cardiovascular or cerebrovascular event or related procedure during the past year. Poorly controlled hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>